StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for TVTX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $43.49 | $42.59 | -2.07% | 1.7M |
| 05-18 | $42.34 | $42.89 | +1.30% | 1.8M |
| 05-19 | $42.66 | $42.26 | -0.94% | 1.3M |
| 05-20 | $42.72 | $43.49 | +1.80% | 1.6M |
| 05-21 | $42.99 | $44.74 | +4.07% | 1.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $127.20M | $490.73M | $361.04M | $196.18M |
Operating Income | $-36.91M | $-62.82M | $-30.40M | $-55.33M |
Net Income | $-37.10M | $-25.55M | $-28.27M | $-53.98M |
EPS (Diluted) | $-0.40 | $-0.29 | $-0.32 | $-0.61 |
Total Assets | $555.19M | $605.19M | $538.58M | $555.31M |
Total Liabilities | $456.46M | $490.36M | $465.02M | $522.56M |
Cash & Equivalents | $78.36M | $93.03M | $110.93M | $75.15M |
Free Cash Flow OCF − CapEx | Not available | Not available | $-23.27M | $-37.45M |
Shares Outstanding | 92.40M | 90.92M | 89.46M | 89.10M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.